World Journal of Gastrointestinal Oncology最新文献

{"title":"Serum ferritin and the risk of early-onset colorectal cancer.","authors":"Adam L Urback, Kylee Martens, Hannah Stowe McMurry, Emerson Y Chen, Caitlin Citti, Anil Sharma, Adel Kardosh, Joseph J Shatzel","doi":"10.4251/wjgo.v16.i8.3496","DOIUrl":"10.4251/wjgo.v16.i8.3496","url":null,"abstract":"<p><strong>Background: </strong>The incidence of early-onset colorectal cancer (EO-CRC) is rising in the United States, and is often diagnosed at advanced stages. Low serum ferritin is often incidentally discovered in young adults, however, the indication for endoscopy in EO-CRC is unclear.</p><p><strong>Aim: </strong>To compare serum ferritin between patients with EO-CRC and healthy controls (HCs), and examine the association of serum ferritin in EO-CRC with patient- and disease-specific characteristics.</p><p><strong>Methods: </strong>A retrospective study of patients < 50 years with newly-diagnosed EO-CRC was conducted from 1/2013-12/2023. Patients were included if serum ferritin was measured within 2 years prior to 1 year following CRC histologic diagnosis. To supplement the analysis, a cohort of HCs meeting similar inclusion and exclusion criteria were identified for comparison. A sensitivity analysis including only patients with serum ferritin obtained at or before diagnosis was separately performed to minimize risk of confounding.</p><p><strong>Results: </strong>Among 85 patients identified with EO-CRC (48 females), the median serum ferritin level was 26 ng/mL (range < 1-2759 ng/mL). Compared to HCs (<i>n</i> = 80211), there were a higher proportion of individuals with EO-CRC with serum ferritin < 20 ng/mL (female 65%, male 40%) versus HCs (female 32.1%, male 7.2%) age 29-39 years (<i>P</i> = 0.002 and <i>P</i> < 0.00001, respectively). Stage IV disease was associated with significantly higher serum ferritin compared to less advanced stages (<i>P</i> < 0.001). Serum ferritin obtained before or at the time of diagnosis was lower than levels obtained after diagnosis. Similar findings were confirmed in the sensitivity analysis.</p><p><strong>Conclusion: </strong>Severe iron deficiency may indicate an increased risk of EO-CRC, particularly at earlier stages. Further studies defining the optimal serum ferritin threshold and routine incorporation of serum ferritin in screening algorithms is essential to develop more effective screening strategies for EO-CRC.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of hepatic arterial infusion chemotherapy and its combination strategies for advanced hepatocellular carcinoma: A network meta-analysis.","authors":"Shun-An Zhou, Qing-Mei Zhou, Lei Wu, Zhi-Hong Chen, Fan Wu, Zhen-Rong Chen, Lian-Qun Xu, Bi-Ling Gan, Hao-Sheng Jin, Ning Shi","doi":"10.4251/wjgo.v16.i8.3672","DOIUrl":"10.4251/wjgo.v16.i8.3672","url":null,"abstract":"<p><strong>Background: </strong>With the rapid progress of systematic therapy for hepatocellular carcinoma (HCC), therapeutic strategies combining hepatic arterial infusion chemotherapy (HAIC) with systematic therapy arised increasing concentrations. However, there have been no systematic review comparing HAIC and its combination strategies in the first-line treatment for advanced HCC.</p><p><strong>Aim: </strong>To investigate the efficacy and safety of HAIC and its combination therapies for advanced HCC.</p><p><strong>Methods: </strong>A network meta-analysis was performed by including 9 randomized controlled trails and 35 cohort studies to carry out our study. The outcomes of interest comprised overall survival (OS), progression-free survival (PFS), tumor response and adverse events. Hazard ratios (HR) and odds ratios (OR) with a 95% confidence interval (CI) were calculated and agents were ranked based on their ranking probability.</p><p><strong>Results: </strong>HAIC outperformed Sorafenib (HR = 0.55, 95%CI: 0.42-0.72; HR = 0.51, 95%CI: 0.33-0.78; OR = 2.86, 95%CI: 1.37-5.98; OR = 5.45, 95%CI: 3.57-8.30; OR = 7.15, 95%CI: 4.06-12.58; OR = 2.89, 95%CI: 1.99-4.19; OR = 0.48, 95%CI: 0.25-0.92, respectively) and transarterial chemoembolization (TACE) (HR = 0.50, 95%CI: 0.33-0.75; HR = 0.62, 95%CI: 0.39-0.98; OR = 3.08, 95%CI: 1.36-6.98; OR = 2.07, 95%CI: 1.54-2.80; OR = 3.16, 95%CI: 1.71-5.85; OR = 2.67, 95%CI: 1.59-4.50; OR = 0.16, 95%CI: 0.05-0.54, respectively) in terms of efficacy and safety. HAIC + lenvatinib + ablation, HAIC + ablation, HAIC + anti- programmed cell death 1 (PD-1), and HAIC + radiotherapy had the higher likelihood of providing better OS and PFS outcomes compared to HAIC alone. HAIC + TACE + S-1, HAIC + lenvatinib, HAIC + PD-1, HAIC + TACE, and HAIC + sorafenib had the higher likelihood of providing better partial response and objective response rate outcomes compared to HAIC. HAIC + PD-1, HAIC + TACE + S-1 and HAIC + TACE had the higher likelihood of providing better complete response and disease control rate outcomes compared to HAIC alone.</p><p><strong>Conclusion: </strong>HAIC proved more effective and safer than sorafenib and TACE. Furthermore, combined with other interventions, HAIC showed improved efficacy over HAIC monotherapy according to the treatment ranking analysis.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334021/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of fecal immunochemical test in colorectal cancer screening: A community-based, cross-sectional study in average-risk individuals in Hainan.","authors":"Fan Zeng, Da-Ya Zhang, Shi-Ju Chen, Run-Xiang Chen, Chen Chen, Shi-Mei Huang, Da Li, Xiao-Dong Zhang, Jia-Jia Chen, Cui-Yi Mo, Lei Gao, Jun-Tao Zeng, Jian-Xin Xiong, Zhai Chen, Fei-Hu Bai","doi":"10.4251/wjgo.v16.i8.3445","DOIUrl":"10.4251/wjgo.v16.i8.3445","url":null,"abstract":"<p><strong>Background: </strong>The incidence of colorectal cancer (CRC) in China is steadily rising, with a high proportion of advanced-stage diagnoses. This highlights the significance of early detection and prevention measures to enhance survival rates. Fecal immunochemical testing (FIT) is a globally recommended CRC screening method; however, limited research has been conducted on its application in Hainan.</p><p><strong>Aim: </strong>To assess the efficacy and adherence of FIT screening among average-risk individuals in Hainan, while also examining the risk factors associated with positive FIT results.</p><p><strong>Methods: </strong>This population-based cross-sectional study implemented FIT screening for CRC in 2000 asymptomatic participants aged 40-75 years from five cities and 21 community health centers in Hainan Province. The study was conducted from August 2022 to April 2023, employing a stratified sampling method to select participants. Individuals with positive FIT results subsequently underwent colonoscopy. Positive predictive values for confirmed CRC and advanced adenoma were calculated, and the relationship between relevant variables and positive FIT results was analyzed using <i>χ</i> ² tests and multivariate logistic regression.</p><p><strong>Results: </strong>A total of 1788 participants completed the FIT screening, with a median age of 57 years (interquartile range: 40-75). Among them, 503 (28.1%) were males, and 1285 (71.9%) were females, resulting in an 89.4% compliance rate for FIT screening. The overall positivity rate of FIT was 4.4% [79 out of 1788; 95% confidence interval (CI): 3%-5%]. The specific positivity rates for Haikou, Sanya, Orient City, Qionghai City, and Wuzhishan City were 9.6% (45 of 468; 95%CI: 8%-11%), 1.3% (6 of 445; 95%CI: 0.1%-3.1%), 2.7% (8 of 293; 95%CI: 1.2%-4.3%), 3.3% (9 of 276; 95%CI: 1.0%-6.3%), and 4.2% (11 of 406; 95%CI: 1.2%-7.3%), respectively. Significant associations were found between age, dietary habits, and positive FIT results. Out of the 79 participants with positive FIT results, 55 underwent colonoscopy, demonstrating an 82.2% compliance rate. Among them, 10 had a clean gastrointestinal tract, 43 had polyps or adenomas, and 2 were confirmed to have CRC, yielding a positive predictive value of 3.6% (95%CI: 0.9%-4.2%). Among the 43 participants with polyps or adenomas, 8 were diagnosed with advanced adenomas, resulting in an advanced adenoma rate of 14.5% (95%CI: 10.1%-17.7%).</p><p><strong>Conclusion: </strong>In the Hainan region, FIT screening for CRC among asymptomatic individuals at average risk is feasible and well-received.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for the prognosis of colon cancer.","authors":"Chu-Ying Wu, Kai Ye","doi":"10.4251/wjgo.v16.i8.3738","DOIUrl":"10.4251/wjgo.v16.i8.3738","url":null,"abstract":"<p><p>A study on clinical outcomes and prognostic factors in T4N0M0 colon cancer patients after R0 resection revealed that ileostomy, T stage, right hemicolectomy, irregular follow-up, and CA199 level were independent risk factors affecting overall survival. T4-stage cancer invades the entire thickness of the intestinal tract, increasing the difficulty of treatment and the risk of recurrence, and requires a combination of chemotherapy, immunotherapy, and targeted therapy to control the spread of cancer cells. The prognosis of right hemicolectomy is significantly worse than that of left hemicolectomy, and right hemicolectomy is an independent risk factor for a poor prognosis. Advanced age, histopathological type, and lymph node metastasis are also risk factors for colon cancer.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating the labyrinth of long non-coding RNAs in colorectal cancer: From chemoresistance to autophagy.","authors":"Jia-Mei Yu, Chong-Qi Sun, Huan-Huan Xu, Ya-Li Jiang, Xing-Yu Jiang, Si-Qi Ni, Ting-Yu Zhao, Ling-Xiang Liu","doi":"10.4251/wjgo.v16.i8.3376","DOIUrl":"10.4251/wjgo.v16.i8.3376","url":null,"abstract":"<p><p>Long non-coding RNAs (lncRNAs), with transcript lengths exceeding 200 nucleotides and little or no protein-coding capacity, have been found to impact colorectal cancer (CRC) through various biological processes. LncRNA expression can regulate autophagy, which plays dual roles in the initiation and progression of cancers, including CRC. Abnormal expression of lncRNAs is associated with the emergence of chemoresistance. Moreover, it has been confirmed that targeting autophagy through lncRNA regulation could be a viable approach for combating chemoresistance. Two recent studies titled \"Human β-defensin-1 affects the mammalian target of rapamycin pathway and autophagy in colon cancer cells through long non-coding RNA TCONS_00014506\" and \"Upregulated lncRNA PRNT promotes progression and oxaliplatin resistance of colorectal cancer cells by regulating HIPK2 transcription\" revealed novel insights into lncRNAs associated with autophagy and oxaliplatin resistance in CRC, respectively. In this editorial, we particularly focus on the regulatory role of lncRNAs in CRC-related autophagy and chemoresistance since the regulation of chemotherapeutic sensitivity by intervening with the lncRNAs involved in the autophagy process has become a promising new approach for cancer treatment.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Camrelizumab, apatinib and hepatic artery infusion chemotherapy combined with microwave ablation for advanced hepatocellular carcinoma.","authors":"Meng-Xuan Zuo, Chao An, Yu-Zhe Cao, Jia-Yu Pan, Lu-Ping Xie, Xin-Jing Yang, Wang Li, Pei-Hong Wu","doi":"10.4251/wjgo.v16.i8.3481","DOIUrl":"10.4251/wjgo.v16.i8.3481","url":null,"abstract":"<p><strong>Background: </strong>Hepatic arterial infusion chemotherapy and camrelizumab plus apatinib (TRIPLET protocol) is promising for advanced hepatocellular carcinoma (Ad-HCC). However, the usefulness of microwave ablation (MWA) after TRIPLET is still controversial.</p><p><strong>Aim: </strong>To compare the efficacy and safety of TRIPLET alone (T-A) <i>vs</i> TRIPLET-MWA (T-M) for Ad-HCC.</p><p><strong>Methods: </strong>From January 2018 to March 2022, 217 Ad-HCC patients were retrospectively enrolled. Among them, 122 were included in the T-A group, and 95 were included in the T-M group. A propensity score matching (PSM) was applied to balance bias. Overall survival (OS) was compared using the Kaplan-Meier curve with the log-rank test. The overall objective response rate (ORR) and major complications were also assessed.</p><p><strong>Results: </strong>After PSM, 82 patients were included both the T-A group and the T-M group. The ORR (85.4%) in the T-M group was significantly higher than that (65.9%) in the T-A group (<i>P</i> < 0.001). The cumulative 1-, 2-, and 3-year OS rates were 98.7%, 93.4%, and 82.0% in the T-M group and 85.1%, 63.1%, and 55.0% in the T-A group (hazard ratio = 0.22; 95% confidence interval: 0.10-0.49; <i>P</i> < 0.001). The incidence of major complications was 4.9% (6/122) in the T-A group and 5.3% (5/95) in the T-M group, which were not significantly different (<i>P</i> = 1.000).</p><p><strong>Conclusion: </strong>T-M can provide better survival outcomes and comparable safety for Ad-HCC than T-A.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colon cancer screening: What to choose?","authors":"Martin Alonso Gomez Zuleta","doi":"10.4251/wjgo.v16.i8.3393","DOIUrl":"10.4251/wjgo.v16.i8.3393","url":null,"abstract":"<p><p>Colorectal cancer is one of the predominant tumors in the world, primarily generated by a progression from polyp to cancer which can last several years, giving a great opportunity to the scientific community for its prevention by screening programs that can be done with invasive and non-invasive tests. In this issue, Lopes <i>et al</i> show us an excellent review of screening, its options, its advantages and disadvantages.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334042/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of acacetin on inhibition of apoptosis in <i>Helicobacter pylori</i>-infected gastric epithelial cell line.","authors":"Qi-Xi Yao, Zi-Yu Li, Hou-Le Kang, Xin He, Min Kang","doi":"10.4251/wjgo.v16.i8.3624","DOIUrl":"10.4251/wjgo.v16.i8.3624","url":null,"abstract":"<p><strong>Background: </strong><i>Helicobacter pylori</i> (<i>H. pylori</i>) infection can cause extensive apoptosis of gastric epithelial cells, serving as a critical catalyst in the progression from chronic gastritis, gastrointestinal metaplasia, and atypical gastric hyperplasia to gastric carcinoma. Prompt eradication of <i>H. pylori</i> is paramount for ameliorating the pathophysiological conditions associated with chronic inflammation of the gastric mucosa and the primary prevention of gastric cancer. Acacetin, which has multifaceted pharmacological activities such as anti-cancer, anti-inflammatory, and antioxidative properties, has been extensively investigated across various domains. Nevertheless, the impact and underlying mechanisms of action of acacetin on <i>H. pylori</i>-infected gastric mucosal epithelial cells remain unclear.</p><p><strong>Aim: </strong>To explore the defensive effects of acacetin on apoptosis in <i>H. pylori</i>-infected GES-1 cells and to investigate the underlying mechanisms.</p><p><strong>Methods: </strong>GES-1 cells were treated with <i>H. pylori</i> and acacetin in vitro. Cell viability was assessed using the CCK-8 assay, cell mortality rate <i>via</i> lactate dehydrogenase assay, alterations in cell migration and healing capacities through the wound healing assay, rates of apoptosis <i>via</i> flow cytometry and TUNEL staining, and expression levels of apoptosis-associated proteins through western blot analysis.</p><p><strong>Results: </strong><i>H. pylori</i> infection led to decreased GES-1 cell viability, increased cell mortality, suppressed cell migration, increased rate of apoptosis, increased expressions of Bax and cle-caspase3, and decreased Bcl-2 expression. Conversely, acacetin treatment enhanced cell viability, mitigated apoptosis induced by <i>H. pylori</i> infection, and modulated the expression of apoptosis-regulatory proteins by upregulating Bcl-2 and downregulating Bax and cleaved caspase-3.</p><p><strong>Conclusion: </strong>Acacetin significantly improved GES-1 cell viability and inhibited apoptosis in <i>H. pylori</i>-infected GES-1 cells, thereby exerting a protective effect on gastric mucosal epithelial cells.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endoscopic detection and diagnostic strategies for minute gastric cancer: A real-world observational study.","authors":"Xiao-Wei Ji, Jie Lin, Yan-Ting Wang, Jing-Jing Ruan, Jing-Hong Xu, Kai Song, Jian-Shan Mao","doi":"10.4251/wjgo.v16.i8.3529","DOIUrl":"10.4251/wjgo.v16.i8.3529","url":null,"abstract":"<p><strong>Background: </strong>Minute gastric cancers (MGCs) have a favorable prognosis, but they are too small to be detected by endoscopy, with a maximum diameter ≤ 5 mm.</p><p><strong>Aim: </strong>To explore endoscopic detection and diagnostic strategies for MGCs.</p><p><strong>Methods: </strong>This was a real-world observational study. The endoscopic and clinicopathological parameters of 191 MGCs between January 2015 and December 2022 were retrospectively analyzed. Endoscopic discoverable opportunity and typical neoplastic features were emphatically reviewed.</p><p><strong>Results: </strong>All MGCs in our study were of a single pathological type, 97.38% (186/191) of which were differentiated-type tumors. White light endoscopy (WLE) detected 84.29% (161/191) of MGCs, and the most common morphology of MGCs found by WLE was protruding. Narrow-band imaging (NBI) secondary observation detected 14.14% (27/191) of MGCs, and the most common morphology of MGCs found by NBI was flat. Another three MGCs were detected by indigo carmine third observation. If a well-demarcated border lesion exhibited a typical neoplastic color, such as yellowish-red or whitish under WLE and brownish under NBI, MGCs should be diagnosed. The proportion with high diagnostic confidence by magnifying endoscopy with NBI (ME-NBI) was significantly higher than the proportion with low diagnostic confidence and the only visible groups (94.19% > 56.92% > 32.50%, <i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>WLE combined with NBI and indigo carmine are helpful for detection of MGCs. A clear demarcation line combined with a typical neoplastic color using nonmagnifying observation is sufficient for diagnosis of MGCs. ME-NBI improves the endoscopic diagnostic confidence of MGCs.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune-related gene characteristics: A new chapter in precision treatment of gastric cancer.","authors":"Lei Gao, Qiang Lin","doi":"10.4251/wjgo.v16.i8.3372","DOIUrl":"10.4251/wjgo.v16.i8.3372","url":null,"abstract":"<p><p>Gastric cancer ranks as the sixth most prevalent cancer worldwide. In recent research within the realm of gastric cancer treatment, the identification and application of immune-related genetic features have emerged as groundbreaking advancements. The study by Ma <i>et al</i>, which developed a prognostic model based on 10 genes, categorizes patients into high and low-risk groups to predict their responsiveness to immune checkpoint inhibitor therapy. This research underscores the potential of immune-related genes as biomarkers for personalized treatment, offering insights into tumor mutation burden and immune phenotype scores. We advocate for further validation, understanding of biological mechanisms, and integration of diverse datasets to enhance the model's predictive accuracy and clinical application, marking a significant step towards personalized and precise treatment for gastric cancer.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334035/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}